Analyst Reco. UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Delayed Nasdaq Other stock markets 15:56:38 2024-06-21 EDT			5-day change	1st Jan Change
16.44 ^USD	+6.27%		-14.48%	+9.47%

06-18	Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Ahead of Speeches by Fed Officials	MT
06-14	Oppenheimer Adjusts UroGen Pharma Price Target to $40 From $32, Maintains Outperform Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts UroGen Pharma Price Target to $40 From $32, Maintains Outperform Rating	06-14	MT
Ladenburg Thalmann Raises Price Target on UroGen Pharma to $53.50 From $48, Maintains Buy Rating	06-14	MT
HC Wainwright Adjusts Price Target on UroGen Pharma to $60 From $54, Maintains Buy Rating	06-14	MT
Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating	05-14	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $34 From $35, Maintains Outperform Rating	03-15	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $35 From $32, Maintains Outperform Rating	01-24	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $32 From $33, Maintains Outperform Rating	11-15	MT
HC Wainwright Adjusts Price Target on UroGen Pharma to $54 From $23, Maintains Buy Rating	23-08-01	MT
Goldman Sachs Adjusts UroGen Pharma Price Target to $18 From $11, Maintains Neutral Rating	23-07-31	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $33 From $22, Maintains Outperform Rating	23-07-28	MT
Jefferies Downgrades UroGen Pharma to Hold From Buy, Adjusts Price Target to $10 From $35	23-02-08	MT
HC Wainwright Adjusts UroGen Pharma's Price Target to $23 From $26, Keeps Buy Rating	22-12-12	MT
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma	22-11-14	CI
Oppenheimer Adjusts UroGen Pharma Price Target to $35 From $21, Maintains Outperform Rating	22-08-12	MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	22-07-01	MT
Berenberg Bank Initiates Coverage on UroGen Pharma With Buy Rating, $20 Price Target	22-04-27	MT
Oppenheimer Adjusts UroGen Pharma Price Target to $21 From $30, Maintains Outperform Rating	22-04-26	MT
Goldman Sachs Adjusts UroGen Pharma's Price Target to $11 from $10, Maintains Neutral Rating	22-03-22	MT
HC Wainwright Adjusts UroGen Pharma's Price Target to $26 From $34, Reiterates Buy Rating	22-03-22	MT
HC Wainwright Adjusts UroGen Pharma's Price Target to $34 From $50, Reiterates Buy Rating	22-01-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Analyst Reco.

Filters